Abstract:Metabolic changes have been suggested to be a hallmark of tumors and are closely associated with tumorigenesis. In a previous study, we demonstrated the role of lactate dehydrogenase in regulating abnormal glucose metabolism in pituitary adenomas (PA). As the key organelle of oxidative phosphorylation (OXPHOS), mitochondria play a vital role in the energy supply for tumor cells. However, few attempts have been made to elucidate mitochondrial metabolic homeostasis in PA. Dynamin-related protein 1 (Drp1) is a member of the dynamin superfamily of GTPases, which mediates mitochondrial fission. This study is aimed at investigating whether Drp1 affects the progression of PA through abnormal mitochondrial metabolism. We analyzed the expression of dynamin-related protein 1 (Drp1) in 20 surgical PA samples. The effects of Drp1 on PA growth were assessed in vitro and in xenograft models. We found an upregulation of Drp1 in PA samples with a low proliferation index. Knockdown or inhibition of Drp1 enhanced the proliferation of PA cell lines in vitro, while overexpression of Drp1 could reversed such effects. Mechanistically, overexpressed Drp1 damaged mitochondria by overproduction of reactive oxygen species (ROS), which induced mitochondrial OXPHOS inhibition and decline of ATP production. The energy deficiency inhibited proliferation of PA cells. In addition, overexpressed Drp1 promoted cytochrome c release from damaged mitochondria into the cytoplasm and then activated the downstream caspase apoptotic cascade reaction, which induced apoptosis of PA cells. Moreover, the decreased ATP production induced by Drp1 overexpressing activated the AMPK cellular energy stress sensor and enhanced autophagy through the AMPK-ULK1 pathway, which might play a protective role in PA growth. Furthermore, overexpression of Drp1 repressed PA growth in vivo. Our data indicates that Drp1-mediated mitochondrial metabolic dysfunction inhibits PA growth by affecting cell proliferation, apoptosis, and autophagy. Selectively targeting mitochondrial metabolic homeostasis stands out as a promising antineoplastic strategy for PA therapy.

Metabolic Abnormalities in Pituitary Adenoma Patients: A Novel Therapeutic Target and Prognostic Factor

The Role of Aberrant Metabolism in Cancer: Insights into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer

Strategy for Identifying a Robust Metabolomic Signature Reveals the Altered Lipid Metabolism in Pituitary Adenoma.

Human Pituitary Adenoma Proteomics: New Progresses And Perspectives

Metabolic Syndrome Components in Patients with Pituitary Adenoma

Autophagy and Pituitary Adenoma

Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review

Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma

The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas

Metabolic Plasticity in Heterogeneous Pancreatic Ductal Adenocarcinoma.

Drp1-Mediated Mitochondrial Metabolic Dysfunction Inhibits the Tumor Growth of Pituitary Adenomas

Metabolic Reprogramming Drives Pituitary Tumor Growth through Epigenetic Regulation of TERT

Application of Metabolomic Studies in Pituitary Adenomas

The Metabolism Symbiosis Between Pancreatic Cancer and Tumor Microenvironment

Energy Sources Identify Metabolic Phenotypes in Pancreatic Cancer

Clinical Biology of the Pituitary Adenoma

Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets

Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC.

Targeting Nrf2-Mediated Oxidative Stress Response Signaling Pathways as New Therapeutic Strategy for Pituitary Adenomas

The Clinical and Pathological Characteristics of Refractory Pituitary Adenomas: A Single Center Experience

Emerging mechanisms and promising approaches in pancreatic cancer metabolism